JP7105057B2 - oral composition - Google Patents

Description

TECHNICAL FIELD The present invention relates to an oral composition and a method for enhancing adhesion of an oral composition to oral mucosa.

Japanese Patent Application Laid-Open No. 60-226806 (Patent Document 1) discloses an oral composition for gum massage for preventing and treating gingivitis and the like. Specifically, it is disclosed that the composition for oral cavity has a predetermined composition, thereby achieving excellent massage effect and high absorbability of the active ingredient blended in the composition for oral cavity.

JP-A-60-226806

In the technical field related to oral compositions, it is pointed out that how well the oral composition adheres to and maintains the oral mucosa in a constantly wet state is important for effectively expressing its efficacy. In oral compositions, water-soluble polymers are generally added for the purpose of imparting adhesion and affinity to the oral mucosa, and technology development to enhance the functions of these water-soluble polymers is underway. there is However, an oral composition having the desired adhesion and affinity to the oral mucosa has not yet been obtained.

The present invention has been made in view of the above circumstances, and an object of the present invention is to provide an oral composition having improved adhesion to the oral mucosa and a method for enhancing the adhesion of the oral composition to the oral mucosa.

Surprisingly, the present inventors found that in an oral composition comprising a combination of a predetermined amount of one or more selected from the group consisting of carbazochrome, carbazochrome derivatives and salts thereof, and a water-soluble polymer, It was found that the adhesion to the oral mucosa was remarkably improved when both components were contained. The present invention was completed based on this finding, and the following inventions are provided.

The oral composition according to the present invention comprises a first component that is at least one selected from the group consisting of carbazochrome, carbazochrome derivatives and salts thereof, and a second component that is a water-soluble polymer. A composition containing 0.04 w/w% or less of the first component.

The second component preferably contains one or more selected from the group consisting of hydroxypropylmethylcellulose, carboxyvinyl polymer, sodium alginate and pullulan.

The second component preferably contains two or more compounds.
The oral cavity composition preferably contains the second component in an amount of 0.001 w/w% or more and 20 w/w% or less.

The oral composition preferably contains a third component that is an oily base. Furthermore, it preferably contains a fourth component that is a non-steroidal anti-inflammatory agent. The fourth component is preferably allantoin.

The method for enhancing adhesion of an oral composition to the oral mucosa according to the present invention adheres the oral composition to the oral cavity.

According to the present invention, it is possible to provide an oral composition having improved adhesion to the oral mucosa and a method for enhancing the adhesion of the oral composition to the oral mucosa.

DETAILED DESCRIPTION OF THE INVENTION Embodiments for carrying out the present invention will be described in detail below. However, the present invention is not limited to the following embodiments.

Here, in this specification, the notation of the form "X to Y" means the upper and lower limits of the range (that is, X to Y or less), and no units are described for X, and units are described only for Y. In that case, the units of X and Y are the same. Furthermore, in this specification, unless otherwise specified, the unit of content "%" means "w/w%" and indicates the same numerical value as "g/100g".

<1. Oral composition>
The oral cavity composition according to the present embodiment contains a first component that is at least one selected from the group consisting of carbazochrome, carbazochrome derivatives, and salts thereof, and a second component that is a water-soluble polymer. , which contains 0.04 w/w% or less of the first component.

[First component]
The oral composition according to this embodiment contains a first component that is at least one selected from the group consisting of carbazochrome, carbazochrome derivatives, and salts thereof.

The first component has a hemostatic action. The mechanism is thought to exhibit hemostatic action by suppressing increased vascular permeability to blood and the like. Among the first component, the derivative of carbazochrome should not be limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable. Derivatives of carbazochrome include, for example, esterified derivatives, etherified derivatives, amidated derivatives, sulfonated derivatives, nitrated derivatives, nitrosated derivatives, halogenated derivatives and the like.

Salts of carbazochrome and derivatives of carbazochrome should not be limited as long as they are pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable. Salts of carbazochrome and carbazochrome derivatives include, for example, alkali metal salts and alkaline earth metal salts. Examples of alkali metal salts include sodium salts and potassium salts. Examples of alkaline earth metal salts include magnesium salts and calcium salts.

Among at least one selected from the group consisting of carbazochrome, carbazochrome derivatives and salts thereof, the first component is preferably sodium carbazochrome sulfonate or carbazochrome, more preferably carbazochrome. Furthermore, one or more selected from the group consisting of carbazochrome, carbazochrome derivatives and salts thereof, which is the first component, can be commercially available. As long as the first component is one or more selected from the group consisting of carbazochrome, carbazochrome derivatives and salts thereof, these may be used singly or in combination of two or more. .

The oral composition contains 0.04 w/w% or less of the first component. That is, the content of the first component in the oral composition is 0.04 w/w% or less based on the total amount of the oral composition. The lower limit of the content of the first component should not be limited as long as it is 0.04 w/w% or less. Therefore, the content of the first component may be more than 0 w / w% and 0.04 w / w% or less, and within this range, the type of the first component, the type and content of other components, the oral composition It can be appropriately selected according to the application and the formulation form thereof. If the content of the first component exceeds 0.04 w/w% based on the total amount of the oral cavity composition, the remarkable effects of the present invention tend to be less likely to appear.

The upper limit of the content of the first component is preferably, for example, 0.03 w/w% or less, and more preferably 0.02 w/w% or less, from the viewpoint of exhibiting the effects of the present invention more remarkably. . The lower limit of the content of the first component should not be limited as described above, but from the viewpoint of exhibiting the effects of the present invention more remarkably and from the viewpoint of feeling during use, it is preferable that it is, for example, 0.001 w/w% or more. It is preferably 0.005 w/w% or more, more preferably 0.01 w/w% or more. Most preferably, the content of the first component is 0.02 w/w%.

[Second component]
The oral composition according to this embodiment contains a second component that is a water-soluble polymer. This second component is contained for the purpose of improving the adhesion and affinity of the oral composition to the oral mucosa. Among the second component, the salt of the water-soluble polymer should not be limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable. As long as the second component is a water-soluble polymer defined by the definition described later, these may be used alone or in combination of two or more. It preferably contains two or more compounds.

Examples of water-soluble polymers chemically include vinyl-based polymers [for example, polyvinyl alcohol (fully or partially saponified), polyvinylpyrrolidone (K25, K30, K90, etc.), carboxyvinyl polymer, polyacrylic acid and their salts (sodium polyacrylate, etc.)], polysaccharides [cellulose-based polymers [e.g. Ethylcellulose, nitrocellulose and their salts (carboxymethylcellulose sodium etc.)], mucopolysaccharides [chondroitin sulfate, alginic acid, hyaluronic acid and their salts (chondroitin sulfate sodium, sodium alginate, sodium hyaluronate etc.) etc.], dextran (dextran 40 and dextran 70), pullulan, xanthan gum, gellan gum, agar, etc.]. Commercially available water-soluble polymers can be used.

The water-soluble polymer preferably has a number average molecular weight of 5,000 or more, more preferably 6,000 or more, even more preferably 7,000 or more, even more preferably 8,000 or more, and 9,000 or more. is particularly preferred, and 10,000 or more is most preferred. The number average molecular weight of the water-soluble polymer may be 5,000,000 or less, preferably 2,000,000 or less, and more preferably 1,000,000 or less.

The water-soluble polymer, which is the second component, is preferably an ionic water-soluble polymer from the viewpoint of exhibiting the effects of the present invention more remarkably. Ionic water-soluble polymers include, for example, carboxyvinyl polymer, polyacrylic acid, carboxymethylcellulose, carboxyethylcellulose, mucopolysaccharide and salts thereof, preferably carboxyvinyl polymer, polyacrylic acid, carboxymethylcellulose and mucopolysaccharide. and salts thereof, more preferably carboxyvinyl polymer, sodium carboxymethylcellulose, alginic acid, sodium alginate, still more preferably carboxyvinyl polymer, sodium carboxymethylcellulose, most preferably carboxyvinyl polymer .

From another point of view, the second component preferably includes vinyl polymers and polysaccharides, more preferably vinyl polymers, and still more preferably carboxyvinyl polymers, polyacrylic acid and salts thereof. Carboxyvinyl polymer is particularly preferred.

From another point of view, the second component is preferably a cellulose-based polymer, a vinyl-based polymer, a mucopolysaccharide, or pullulan, and one or two selected from the group consisting of hydroxypropylmethylcellulose, carboxyvinyl polymer, sodium alginate, and pullulan. More preferably, it contains more than one species.

The content of the second component in the oral composition should not be restricted. Therefore, the content of the second component can be appropriately selected according to its type, the type and content of other components, the application of the oral composition, its formulation form, and the like. From the viewpoint of exhibiting the effects of the present invention more remarkably, the oral composition preferably contains the second component in an amount of 0.001 w/w% or more and 20 w/w% or less. That is, the content of the second component in the oral composition is preferably 0.001 to 20 w/w% based on the total amount of the oral composition. The content of the second component is more preferably 0.01 to 10 w/w%, most preferably 0.1 to 10 w/w%. Among them, it is particularly preferable that the amount is 5 w/w% or less.

The content ratio of the first component and the second component in the oral composition should not be restricted. Therefore, the content ratio of the first component and the second component is appropriately selected according to the types of the first component and the second component, the types and contents of other components, the use of the oral composition and its formulation form, etc. can do. From the viewpoint of exhibiting the effects of the present invention more remarkably, the content ratio of the first component and the second component is, for example, 0.1 to 0.1 parts by mass of the second component with respect to 1 part by mass of the first component contained in the oral composition. It is preferably 5000 parts by mass. More preferably, the amount of the second component is 1 to 1,000 parts by mass with respect to 1 part by mass of the first component, and more preferably 5 to 500 parts by mass of the second component with respect to 1 part by mass of the first component. Among them, it is also preferable that the amount of the second component is 50 parts by mass or more, 70 parts by mass or more, or 90 parts by mass or more with respect to 1 part by mass of the first component.

[Third component]
The oral cavity composition according to the present embodiment preferably further contains a third component, which is an oily base, in addition to the first component and the second component. When the composition for oral cavity of the present embodiment further contains a third component together with the first component and the second component, the effects of the present invention are exhibited more remarkably.

The oily base, which is the third component, should not be limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable. As long as the third component is a specific compound described later as an oily base, these may be used singly or in combination of two or more.

Examples of such an oily base include one or two selected from the group consisting of paraffins such as petrolatum, solid paraffin, liquid paraffin, and light liquid paraffin, white petrolatum, microcrystalline wax, bleached beeswax, and gelled hydrocarbons. The above can be mentioned. Among the above, white petrolatum, liquid paraffin, light liquid paraffin, microcrystalline wax, bleached beeswax and gelatinized hydrocarbons are preferably used. Among them, paraffins are preferred, and liquid paraffin and light liquid paraffin are more preferred. A commercially available oily base can also be used.

The content of the third component in the oral composition should not be restricted. The content of the third component can be appropriately selected according to its type, the type and content of other components, the use of the oral composition, its formulation form, and the like. From the viewpoint of exhibiting the effects of the present invention more remarkably, the content of the third component in the oral composition is preferably, for example, 1 to 95 w/w%, based on the total amount of the oral composition, and 3 to 90 w/w% is more preferred, 10 to 90 w/w% is even more preferred, 30 to 90 w/w% is even more preferred, and 40 to 90 w/w% is particularly preferred. , 50-85 w/w %.

The content ratio of the first component and the third component in the oral composition should not be restricted. The content ratio of the first component and the third component is appropriately selected according to the types of the first component and the third component, the types and contents of other components, the use of the oral composition and its formulation form, etc. be able to. From the viewpoint of exhibiting the effect of the present invention more remarkably, the content ratio of the first component and the third component is, for example, 5 to 100,000 parts by mass of the third component per 1 part by mass of the first component contained in the oral composition. It is preferable that it is a part. More preferably, the amount of the third component is 10 to 100,000 parts by mass with respect to 1 part by mass of the first component, and more preferably 100 to 50,000 parts by mass of the third component with respect to 1 part by mass of the first component. More preferably, the amount of the third component is 500 to 10,000 parts by mass based on 1 part by mass of the first component, and most preferably 1,000 to 5,000 parts by mass of the third component based on 1 part by mass of the first component.

The content ratio of the second component and the third component in the oral composition should not be restricted. The content ratio of the second component and the third component is appropriately selected according to the types of the second component and the third component, the types and contents of other components, the use of the oral composition and its formulation form, etc. be able to. From the viewpoint of exhibiting the effects of the present invention more remarkably, the content ratio of the second component and the third component is, for example, 0.01 to 0.01 part by mass of the third component per 1 part by mass of the second component contained in the oral cavity composition. It is preferably 1000 parts by mass. More preferably, the third component is 0.05 to 100 parts by mass with respect to 1 part by mass of the second component, and more preferably 0.1 to 50 parts by mass of the third component with respect to 1 part by mass of the second component. and most preferably 1 to 20 parts by mass of the third component per 1 part by mass of the second component.

[Fourth component]
The oral composition according to this embodiment preferably contains a fourth component that is a non-steroidal anti-inflammatory agent. When the composition for oral cavity further contains the fourth component together with the first component and the second component, the effects of the present invention are exhibited more remarkably. By further containing the third component, the effects of the present invention are exhibited more remarkably. In addition, since the oral composition according to the present embodiment has improved adhesion to the oral mucosa, the anti-inflammatory effect of the fourth component and the The tissue repair effect can be exhibited more efficiently.

The fourth component, the non-steroidal anti-inflammatory agent, should not be limited as long as it is pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable. As long as the fourth component is a specific compound described later as an anti-inflammatory agent, these may be used singly or in combination of two or more.

Examples of such non-steroidal anti-inflammatory agents include allantoin, aldioxa, ictamol, glycyrrhizic acid, glycyrrhetinic acid, salicylic acid, dimethylisopropylazulene, indomethacin, epsilon-aminocaproic acid, berberine, pranoprofen, azulene sulfonic acid, diclofenac, bromfenac. , tranexamic acid, lysozyme chloride, bromelain, serrapeptase, ibuprofen piconol, presterone, derivatives thereof (allantoin chlorhydroxyaluminum, allantoin dihydroxyaluminum, methyl salicylate, salicylic acid monoglycol ester, etc.), and salts thereof One or two or more compounds are included. Furthermore, as non-steroidal anti-inflammatory agents, tinctures having anti-inflammatory effects (chamomile tincture, myrrh tincture, ratania tincture, lichen extract, etc.) can also be used. A commercially available anti-inflammatory agent can also be used.

Among the above, preferably one or more compounds selected from the group consisting of allantoin, glycyrrhizic acid, glycyrrhetinic acid, salicylic acid, epsilon-aminocaproic acid, azulene sulfonic acid, chamomile tincture, derivatives thereof and salts thereof. be. Furthermore, one or more compounds selected from the group consisting of allantoin, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, β-glycyrrhetinic acid, allantoin chlorohydroxyaluminum, allantoin dihydroxyaluminum, epsilon-aminocaproic acid, chamomile tincture more preferably allantoin and/or dipotassium glycyrrhizinate, most preferably allantoin.

The content of the fourth component in the oral composition should not be restricted. The content of the fourth component can be appropriately selected according to its type, the type and content of other components, the application of the oral composition, its formulation form, and the like. From the viewpoint of exhibiting the effects of the present invention more remarkably, the content of the fourth component in the oral composition is preferably, for example, 0.001 to 10 w/w% based on the total amount of the oral composition, More preferably 0.01 to 5 w/w%, most preferably 0.1 to 1 w/w%.

The content ratio of the first component and the fourth component in the oral composition should not be restricted. The content ratio of the first component and the fourth component is appropriately selected according to the types of the first component and the fourth component, the types and contents of other components, the use of the oral composition and its formulation form, etc. be able to. From the viewpoint of exhibiting the effect of the present invention more remarkably, the content ratio of the first component and the fourth component is, for example, 0.01 to 0.01 to 1 part by mass of the first component contained in the oral composition. It is preferably 1000 parts by mass. More preferably, the fourth component is 0.1 to 500 parts by mass with respect to 1 part by mass of the first component, and more preferably 1 to 100 parts by mass of the fourth component with respect to 1 part by mass of the first component. , most preferably 10 to 50 parts by weight of the fourth component per 1 part by weight of the first component.

The content ratio of the second component and the fourth component in the oral composition should not be restricted. The content ratio of the second component and the fourth component is appropriately selected according to the types of the second component and the fourth component, the types and contents of other components, the use of the oral composition and its formulation form, etc. be able to. From the viewpoint of exhibiting the effects of the present invention more remarkably, the content ratio of the second component and the fourth component is, for example, 0.00005 to 0.00005 to 1 part by mass of the second component contained in the oral cavity composition. It is preferably 1000 parts by mass. More preferably, the fourth component is 0.0001 to 100 parts by mass with respect to 1 part by mass of the second component, and more preferably 0.0005 to 10 parts by mass of the fourth component with respect to 1 part by mass of the second component. More preferably, the fourth component is 0.001 to 4 parts by mass relative to 1 part by mass of the second component, and most preferably the fourth component is 0.01 to 4 parts by mass relative to 1 part by mass of the second component. 1 part by mass.

[Other active ingredients (drug ingredients)]
The oral cavity composition according to the present embodiment can contain other active ingredients (drug ingredients) in addition to the above components. Since the oral composition according to the present embodiment has improved adhesion to the oral mucosa, the effects of these drug components are more efficiently exhibited at the initial stage and over time after the oral composition is adhered to the affected area. can be exhibited. Examples of the active ingredients (drug ingredients) include bactericides, antihistamines, tissue repair agents, local anesthetics, herbal medicines, vitamins, steroidal anti-inflammatory agents, and other ingredients. The above active ingredients (drug ingredients) may be used singly or in combination of two or more selected from the group consisting of these.

Bactericides such as iodine, potassium iodide, liquid phenol, phenol, cetylpyridinium chloride, dequalinium chloride, creosote, thymol, triclocarban, benzalkonium chloride, benzethonium chloride, acrinol, oxidol, ethanol, isopropanol, mercurochrome, cresol , isopropylmethylphenol, phenyl salicylate, sulfadiazine, homosulfamine, cinnamon bark oil, and hinokitiol. In addition, it is preferable that the composition for oral cavity according to the present embodiment does not contain chlorhexidine gluconate. This is to eliminate the possibility of anaphylactic shock occurring when it is contained.

Antihistamines such as chlorpheniramine maleate, diphenhydramine salicylate, diphenylpyraline hydrochloride, mequitazine, triprolidine hydrochloride, carbinoxamine maleate, diphenhydramine hydrochloride, diphenhydramine tannate, dimenhydrinate, promethacin hydrochloride, promethazine teoclate, meclizine hydrochloride, isopentyl hydrochloride etc.

Examples of tissue repair agents include sodium copper chlorophyllin, methylmethionine sulfonium chloride, sucralfate, cetraxate hydrochloride, sofalcon, gefarnate, trimebutine maleate, teprenone, heparin analogs and the like.

Local anesthetics include, for example, dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, ethyl aminobenzoate, oxethazaine, and tecaine.

Examples of herbal medicines include cinnamon bark, cinnamon bark oil, psychedelic bark, cinnamon bark, Phellodendron bark, clove components, Corydalis, camphor, bellflower, safflower, and the like.

Vitamins such as vitamin A oil, retinol palmitate, retinol acetate, ascorbic acid, sodium ascorbate, calcium ascorbate, tocopherol, tocopherol acetate, tocopherol succinate, calcium tocopherol succinate, panthenol, sodium pantothenate, pantothenic acid Calcium, pyridoxine hydrochloride, pyridoxal phosphate, vitamin B2, riboflavin, riboflavin sodium phosphate, riboflavin butyrate, flavin adenine dinucleotide sodium, hydroxocobalamin hydrochloride, hydroxocobalamin acetate, cyanocobalamin, hydroxocobalamin, nicotinamide, biotin, thiamine hydrochloride, Thiamine nitrate, bistiamine nitrate, thiamine disulfide, thiamine dicetyl sulfate, dicetiamine hydrochloride, fursultiamine hydrochloride, octotiamine, sicotiamine, bisivetiamine, bisbentiamine, fursultiamine, prosultiamine, benfotiamine, etc. mentioned.

Steroidal anti-inflammatory agents such as prednisolone, beclomethasone, triamcinolone, betamethasone, fluticasone, dexamethasone, hydrocortisone, and esters thereof (more specifically, esters thereof with propionic acid, acetic acid, butyric acid, or valeric acid, For example, triamcinolone acetonide, etc.).

Other ingredients include local protective agents such as glycerin and concentrated glycerin, local irritants such as l-menthol, peppermint oil, and dl-menthol, tissue astringents such as hinokitiol, and blood circulation promoters such as benzyl nicotinate and sodium polyethylene sulfonate. , antibiotics such as minocycline hydrochloride.

〔Additive〕
The oral composition according to the present embodiment can contain various additives according to conventional methods, depending on its use and formulation form, as long as the effects of the present invention are not impaired. Examples of such additives include various additives described in "Pharmaceutical Excipients Encyclopedia 2007" (edited by Japan Pharmaceutical Excipients Association).

Typical examples of additives include light silicic anhydride, silicic anhydride, pH adjusters, antioxidants, chelating agents, oils, coloring agents, fragrances, wetting agents, surfactants, solvents and the like.

pH adjusters such as citric acid, adipic acid, tartaric acid, maleic acid, isocitric acid, fumaric acid, malic acid, succinic acid, gluconic acid, lactic acid, malonic acid, glutaric acid, glutaconic acid, aspartic acid, glutamic acid, pimelic acid , oxalic acid, glycolic acid, glyceric acid, pyruvic acid, acrylic acid, methacrylic acid, suberic acid, azelaic acid, mevalonic acid, ethylenediaminetetraacetic acid, phthalic acid, terephthalic acid, oxyacetic acid, phenylsuccinic acid, ethylmalonic acid, pivaline acid, undecanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, N-palmitoyl-L-glutamic acid, ascorbic acid, pyrrolidonecarboxylic acid, sulfamic acid, gluconodeltalactone, phosphoric acid, monopotassium phosphate , monosodium phosphate, calcium hydrogen phosphate, carbonic acid, and acidic substances such as boric acid.

Examples of antioxidants include tocopherols [tocopherol, tocopherol derivatives (tocopherol esters such as tocopherol acetate and tocopherol succinate)], fat-soluble antioxidants such as dibutylhydroxytoluene and butylhydroxyanisole, vitamin C, hydroquinone, cysteine, and glutathione. and water-soluble antioxidants such as

Chelating agents include, for example, sodium edetate, citric acid, sodium citrate and the like.

Examples of oils include sesame oil, castor oil, soybean oil, olive oil, squalane, and refined lanolin.

Examples of coloring agents include Red No. 3, Blue No. 1, Yellow No. 4, Green No. 3, and titanium dioxide.

Flavoring agents include natural oils such as peppermint oil, spearmint oil, eucalyptus oil, wintergreen oil, clove oil, thyme oil, sage oil, cardamom oil, rosemary oil, marjoram oil, lemon oil, nutmeg oil, lavender oil and paracress oil. Essential oil, l-menthol, l-carvone, cinnamic aldehyde, orange oil, anethole, 1,8-cineole, methyl salicylate, eugenol, thymol, linalool, limonene, menthone, menthyl acetate, citral, camphor, borneol, pinene, spiranthol Perfume ingredients contained in the above natural essential oils such as ethyl acetate, ethyl butyrate, isoamyl acetate, hexanal, hexenal, methyl anthranilate, ethyl methylphenyl glycidate, benzaldehyde, vanillin, ethyl vanillin, furaneol, maltol, ethyl Perfume ingredients such as maltol, gamma/delta decalactone, gamma/delta decalactone, N-ethyl-p-menthane-3-carboxamide, menthyl lactate, ethylene glycol-l-menthyl carbonate, and the like.

Furthermore, as a flavor, apple, banana, strawberry, blueberry, melon, peach, pineapple, grape, muscat, wine, cherry, which are obtained by combining one or two or more ingredients selected from the group consisting of the above-mentioned flavoring ingredients and natural essential oils. , squash, coffee, brandy, and yogurt.

Wetting agents such as glycerin, propylene glycol, polyethylene glycol (Macrogol 200, Macrogol 400, Macrogol 600, Macrogol 1000, Macrogol 1500, Macrogol 1540, Macrogol 4000, Macrogol 6000, etc.), sorbitol, 1 , polyhydric alcohols such as 3-butylene glycol, starch syrup, and the like.

Examples of surfactants include nonionic surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants. As nonionic surfactants, POE hydrogenated castor oil, POE sorbitan fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, (poly)glycerin fatty acid ester, fatty acid sorbitan, (poly)propylene glycol fatty acid ester, POE glycerin fatty acid ester, POE alkyl ethers, POE-POP alkyl ethers, POE fatty acid esters, and the like. Anionic surfactants include alkyl sulfates such as sodium lauryl sulfate. Examples of cationic surfactants include alkylammonium types. Examples of amphoteric surfactants include betaine type and imidazoline type.

Examples of solvents include water, ethanol, glycerin, 1,3-butylene glycol and the like.

[Dosage form]
The oral composition according to the present embodiment is in the form of liquid, paste, gel, or the like, and includes dentifrices such as toothpaste, wet toothpaste, and liquid toothpaste, mouth washes, gels, ointments, and mouth fresheners. , tablets for gargling, pasta for oral cavity, gum and the like. Furthermore, depending on the dosage form, known ingredients other than the first component and the second component can be blended within a range that does not impair the effect of the present invention, and can be prepared according to a conventional method.

The composition for oral cavity according to the present embodiment is preferably an ointment for oral cavity from the viewpoint of exhibiting the effects of the present invention more remarkably. In the case of an oral ointment, the usage and dosage are, for example, in the case of adults (15 years old and over) and children over 7 years old, a method of applying it to the gums twice a day. However, it should not be limited to this as long as it is a usage and dosage with few side effects.

The composition for oral cavity according to the present embodiment is also preferably an oral cream from the viewpoint of exhibiting the effects of the present invention more remarkably. In the case of an oral cream, the usage and dosage are, for example, in the case of adults (ages 15 and over) and children aged 7 and over, twice a day with a toothbrush to massage the gums. As long as the effects of the present invention are exhibited and side effects are minimal, the usage and dosage should not be limited to this.

The oral composition according to the present embodiment is exemplified by a form in which it is housed in a laminated container in which a part or all of the portion that comes into contact with the oral composition is made of aluminum, for example. Furthermore, a form in which it is housed in a container made of glass or plastic and provided is also exemplified.

[Hardness of composition for oral cavity]
The hardness of the oral cavity composition according to this embodiment should not be limited as long as it is within a pharmaceutically, pharmacologically (pharmaceutical) or physiologically acceptable range. However, from the viewpoint of exhibiting the effects of the present invention more remarkably, the lower limit of the hardness of the oral composition is preferably 15 g or more, more preferably 20 g or more, and even more preferably 30 g or more. , 40 g or more, and most preferably 50 g or more. The upper limit of hardness is preferably 1000 g or less, more preferably 500 g or less, and even more preferably 300 g or less.

Here, the hardness of the composition for oral cavity can be measured by the following method. That is, using a rheometer (trade name (product number): FUDOH RHEO METER (RT2100D/D-CW), manufactured by Rheotec Co., Ltd.), T.I. Speed (UP) 2 cm / min, 25 ° C., a plastic ointment pot (A-55 (55 cc), MI Chemical Co., Ltd.) with a dedicated adapter of φ 20 (compressive elasticity) to the oral composition. The hardness of the oral cavity composition can be measured by taking the maximum value of hardness (g) recorded until the depth reaches 1 cm.

[Adhesion of Oral Composition]
The oral composition according to the present embodiment contains the first component and the second component, and contains 0.04 w/w% or less of the first component, thereby significantly improving the adhesion to the oral mucosa. can get. This effect is based on the fact that the composition for oral cavity according to the present embodiment swells with moisture such as saliva in the oral cavity, and thus has a property of being more likely to adhere to affected areas such as gums than before swelling. Therefore, whether or not the adhesiveness of the composition for oral cavity according to the present embodiment to the oral mucosa is improved can be evaluated by the following method.

That is, when a predetermined probe is inserted into the swollen oral cavity composition and then pulled up, the amount of the probe attached to the probe (hereinafter also referred to as the "attachment amount of the probe after swelling") is measured by the method described later. do. Furthermore, the amount of attached probe after swelling is measured by the same method for a composition that does not contain both the first component and the second component (hereinafter also referred to as "comparative composition"). By comparing the probe attachment amount after swelling of the comparative composition obtained by this and the probe attachment amount after swelling of the oral cavity composition of this embodiment, when the attachment amount increased, the oral cavity of this embodiment A composition for oral hygiene can be defined as having improved adhesion to the oral mucosa.

The method for measuring the amount of attached probe after swelling of each composition is as follows. First, an oral composition is prepared by a conventional method. Comparative compositions are also prepared by conventional methods. Next, 2 mL of purified water was added to each of 2 g of the oral composition and 2 g of the comparative composition, stirred and mixed, and then allowed to stand at 30° C. for 24 hours to swell, thereby swelling the oral composition. A body and a swollen body of the comparison composition are obtained. After that, 1.5 g of these swollen bodies are filled in a 20 mL capacity screw cap bottle (manufactured by Nichiden Rika Glass Co., Ltd.).

After that, using the FUDOH RHEO METER, insert a dedicated probe of φ1 cm toward the surface of the swollen body filled in the screw cap bottle until the tip adheres to the surface of the swollen body, and continuously at a speed of 2 cm / min. The swollen body is adhered to the probe by pulling up the probe, and the amount (mass) of the swollen body adhered to the probe is measured. At this time, the greater the amount of swollen material adhering to the probe, the better the adherence to the oral mucosa. This is because the greater the amount of swollen material adhering to the probe, the easier it is to adhere to affected areas such as gums.

Finally, by substituting the probe adhesion amount after swelling of the comparative composition and the probe adhesion amount after swelling of the oral composition into the following formula (1), the "adhesion amount change rate (%)" is It is evaluated whether the adhesion of the oral composition to the oral mucosa is improved. The "attachment amount change rate (%)" is a positive number, and the larger the value, the more the swollen body of the oral composition adhered to the probe compared to the swollen body of the comparative composition. . Therefore, when the "attachment amount change rate (%)" is a positive number and is large, it can be evaluated that the oral composition has improved adhesion to the oral mucosa.

Attached amount change rate (%) = {(Amount of probe attached after swelling of oral composition (g) - Amount of probe attached after swelling of comparative composition (g)) / Amount of probe attached after swelling of comparative composition (g)}×100 (1).

[Action]
As described above, the present embodiment can provide an oral composition having improved adhesion to the oral mucosa.

[Target disease (use)]
The target disease (use) of the oral composition according to the present invention should not be particularly limited as long as it is for oral use, but for example, alleviation of swollen gums, bleeding, pain, pus, alveolar pyorrhea and stomatitis. , amelioration, inhibition or treatment. Furthermore, it is expected to have a tissue repairing effect on the gums and a regenerating effect on the gums and the periodontal ligament.

<2. Method for Enhancing Adhesion of Oral Composition to Oral Mucosa>
The method for enhancing adhesion of the oral composition to the oral mucosa according to the present embodiment is to adhere the oral composition to the oral cavity. Specifically, a first step of preparing a first component that is one or more selected from the group consisting of carbazochrome, carbazochrome derivatives and salts thereof, and a second component that is a water-soluble polymer; and a second step of preparing an oral composition comprising a component and said second component. In the second step, it is preferable to blend the first component in an amount of 0.04 w/w% or less with respect to the total amount of the oral cavity composition. By blending 0.04 w/w% or less of the first component and the second component, respectively, the adhesiveness of the oral composition to the oral mucosa can be significantly improved.

[First step]
In the first step, a first component, which is one or more selected from the group consisting of carbazochrome, carbazochrome derivatives, and salts thereof, and a second component, which is a water-soluble polymer, are prepared. The types of the first component and the second component used in the first step are <1. composition for oral cavity>. Furthermore, in the first step, <1. The third component, fourth component, other active ingredients and additives described in Oral Composition> may be prepared as necessary for preparing the oral composition in the second step described later.

[Second step]
In the second step, an oral composition containing the first component and the second component is prepared. Here, the first and second components prepared in the first step, and the third and fourth components prepared as necessary, other active ingredients and additives can be prepared according to conventional methods. At this time, 0.04 w/w% or less of the first component is blended with respect to the total amount of the oral composition. The amount of the second component to be blended in the second step, the types and blending amounts of other components, etc. are described in <1. composition for oral cavity>. Regarding the formulation form and use of the composition for oral cavity manufactured according to the present embodiment, <1. composition for oral cavity>.

EXAMPLES The present invention will be described in more detail below with reference to Examples, but the present invention is not limited to these.

[Production of oral composition]
An oral composition of Example 1 was produced by preparing each component shown in Table 1 and preparing an oral composition comprising each component according to a conventional method. Further, each component shown in Table 1 was prepared, and comparative compositions of Comparative Examples 1 and 2 were produced in the same manner as in Example 1. "Carboxyvinyl polymer" in Table 1 is a water-soluble polymer and was blended as the second component in this example. "Macrogol 400" and "Macrogol 4000" in Table 1 are polyethylene glycols, respectively, which were added to the oral compositions of Examples and Comparative Examples as humectants (additives).

[Test Example 1]
[Measurement and evaluation of probe adhesion amount after swelling of oral composition]
To 2 g of the oral composition of Example 1 and 2 g of the comparative compositions of Comparative Examples 1 and 2, 2 mL of purified water was added, mixed with stirring, and allowed to stand at 30° C. for 24 hours to swell. A swollen body of the oral cavity composition of Example 1 and swollen bodies of the comparative compositions of Comparative Examples 1 and 2 were obtained. After that, 1.5 g of these swollen bodies were filled in the above-described screw cap bottles (manufactured by Nichiden Rika Glass Co., Ltd.) having a capacity of 20 mL.

Then, using the FUDOH RHEO METER, insert a dedicated probe of φ1 cm toward the surface of the swollen body filled in the screw cap bottle until the tip adheres to the surface of the swollen body, and then at a speed of 2 cm / min. The swollen body was adhered to the probe by pulling up the probe, and the amount (mass) of the swollen body attached to the probe was measured.

Based on the above measurements, by substituting the probe adhesion amount after swelling of the comparative composition of Comparative Example 1 and the probe adhesion amount of the comparative composition of Comparative Example 2 after swelling into the following formula (2), "adhesion Amount change rate (%)” was used to evaluate whether or not the comparative composition of Comparative Example 2 improved adhesion to the oral mucosa compared to the comparative composition of Comparative Example 1. Furthermore, by substituting the probe adhesion amount after swelling of the comparative composition of Comparative Example 1 and the probe adhesion amount after swelling of the oral cavity composition of Example 1 into the following formula (3), "change in adhesion amount As a rate (%)", it was evaluated whether the oral composition of Example 1 improved adhesion to the oral mucosa compared to the comparative composition of Comparative Example 1. As described above, when the value of the "adhesion amount change rate (%)" is a positive number and is large, it can be evaluated that the oral composition has improved adhesion to the oral mucosa. Table 1 shows the results.

Equations (2) and (3) are as follows.
Attached amount change rate (%)={(Amount of probe attached after swelling of the comparative composition of Comparative Example 2 (g)−Amount of probe attached after swelling of the comparative composition of Comparative Example 1 (g))/Comparative Example 1 Probe adhesion amount after swelling of the comparative composition (g)} × 100 (2)
Attached amount change rate (%) = {(Amount of probe attached after swelling of the oral composition of Example 1 (g) - Amount of probe attached after swelling of the comparative composition of Comparative Example 1 (g)) / Comparative Example Amount of attached probe (g) after swelling of comparative composition No. 1}×100 (3).

From Table 1, the oral composition of Example 1 showed a change in the amount of adhesion that increased the amount of adhesion by 8.5% relative to the comparative composition of Comparative Example 1. Therefore, the adhesion to the oral mucosa was understood to be improving. Furthermore, since the comparative composition of Comparative Example 2 contains carbazochrome in its composition, it is understood that the adhesion to the oral mucosa is improved compared to the comparative composition of Comparative Example 1, but the content is not 0.04 w/w% or less, the adhesion to the oral mucosa was not significantly improved as compared with the oral composition of Example 1. That is, the oral composition of Example 1 contains the first component having a content of 0.02 w / w% (0.04 w / w% or less) and the second component, so that the composition in Comparative Examples 1 and 2 In comparison, the adhesiveness to the oral mucosa is remarkably improved.

[Test Example 2]
[Measurement and Evaluation of Swellability of Oral Composition]
0.5 g of the oral composition of Example 1 and 0.5 g of the comparative compositions of Comparative Examples 1 and 2 were each added to a 2.5 mL plastic syringe (trade name: "Terumo Syringe", Terumo Co., Ltd. (manufactured by the company) with the plunger removed. After measuring the total mass of the filled composition and plastic syringes, 300 μL of purified water was added to each syringe. Furthermore, the cap portion (cut from the tube) of a 2 mL capacity tube (“trade name”: BIO-BIK Microtube, manufactured by Ina Optica Co., Ltd.) was attached to the plunger insertion port of the syringe. Next, the syringe is held so that the longitudinal direction of the syringe is vertical and the portion to which the cap is attached is located on the upper side of the syringe, and left at room temperature for 24 hours to swell the oral cavity composition. let me After that, the injection barrel was turned upside down so that the portion where the cap portion was attached was placed on the lower side, and the injection barrel was leaned at an angle of 50° and left for 3 minutes to prevent swelling. Purified water was guided to the cap portion. Finally, the cap portion was removed, and the mass of the composition remaining in the injection barrel was measured.

By substituting the mass of the composition before and after swelling into the following formula (4), the swelling rate (%) of the oral composition of Example 1 and the comparative compositions of Comparative Examples 1 and 2 was calculated. . It can be evaluated that the larger the value of this "swelling ratio (%)" is, the easier the swelling is, and the faster the adhesiveness is exhibited. Table 2 shows the difference in expansion rate (%) between Example 1 and Comparative Example 2 and Comparative Example 1.

Equation (4) is as follows.
Swelling rate (%)=mass after swelling (g)/mass before swelling (g)×100 (4).

From Table 2, the oral composition of Example 1 had an improved swelling rate of 4.2% compared to the comparative composition of Comparative Example 1, so swelling easily occurred when applied to the oral mucosa, and the oral cavity It is understood to be a state in which adhesion to mucous membranes is likely to occur. Furthermore, since the comparative composition of Comparative Example 2 contains carbazochrome in its composition, it is understood that the comparative composition of Comparative Example 1 has improved swelling properties, but the composition for oral cavity of Example 1 The improvement in swelling property was slight compared to the product. That is, the oral composition of Example 1 contains a first component having a carbazochrome content of 0.02 w/w% (0.04 w/w% or less) and a second component. , 2, the swelling property in the oral mucosa is remarkably improved.

Furthermore, the oral composition of Example 1 has improved swelling properties, so that it not only quickly adheres to the oral mucosa, but also when it is applied to the oral mucosa and swells, the oral composition is more tightly packed. Since it is in contact with the application part, it is possible to improve the adhesion between the oral composition and the application part. At the same time, the retention effect in the applied part is enhanced. For example, by retaining in the periodontal pocket, the effect of each component on the periodontal ligament existing inside the gums can be enhanced.

[Test Example 3]
[Production of oral composition]
The oral compositions of Examples 2 to 4 were produced by preparing each component shown in Table 3 and preparing an oral composition comprising each component according to a conventional method. Furthermore, each component shown in Table 3 was prepared, and comparative compositions of Comparative Examples 3 to 5 were produced in the same manner as in Examples 2 to 4. "Hypromellose 2910", "sodium alginate" and "pullulan" in Table 3 are water-soluble polymers and thus are the second component. "Allantoin" in Table 3 is a fourth component because it is a non-steroidal anti-inflammatory drug. "Macrogol 400" and "Macrogol 4000" in Table 3 are polyethylene glycols and therefore are humectants (additives).

[Measurement and evaluation of probe adhesion amount after swelling of oral composition]
To each 2 g of the oral compositions of Examples 2 to 4 and 2 g of the comparative compositions of Comparative Examples 3 to 5, 2 mL of purified water was added, stirred and mixed, and left at 30 ° C. for 24 hours. The swollen bodies of the compositions for oral use of Examples 2 to 4 and the swollen bodies of the comparative compositions of Comparative Examples 3 to 5 were obtained by swelling with a pressure of 100 rpm. After that, 1.5 g of these swollen bodies were filled in the same 20-mL screw cap bottle as used in Test Example 1, respectively.

Then, using the FUDOH RHEO METER, insert a dedicated probe of φ1 cm toward the surface of the swollen body filled in the screw cap bottle until the tip adheres to the surface of the swollen body, and then at a speed of 2 cm / min. The swollen body was adhered to the probe by pulling up the probe, and the amount (mass) of the swollen body attached to the probe was measured.

Based on the above measurements, by substituting the probe adhesion amount after swelling of the comparative composition of Comparative Example 3 and the probe adhesion amount of the oral cavity composition of Example 2 after swelling into the following formula (5), " As a change rate (%) of adhesion amount, it was evaluated whether or not the oral composition of Example 2 improved adhesion to the oral mucosa as compared with the comparative composition of Comparative Example 3.

Furthermore, by substituting the probe adhesion amount after swelling of the comparative composition of Comparative Example 4 and the probe adhesion amount after swelling of the oral cavity composition of Example 3 into the following formula (6), the "adhesion amount change rate (%)”, it was evaluated whether or not the oral composition of Example 3 had improved adhesion to the oral mucosa compared to the comparative composition of Comparative Example 4. By substituting the probe adhesion amount after swelling of the comparative composition of Comparative Example 5 and the probe adhesion amount after swelling of the oral cavity composition of Example 4 into the following formula (7), the "adhesion amount change rate ( %)”, whether or not the oral composition of Example 4 has improved adhesion to the oral mucosa compared to the comparative composition of Comparative Example 5 was also evaluated.

As in Test Example 1, when the "adhesion amount change rate (%)" is a positive number and the value is large, it can be evaluated that the oral composition has improved adhesion to the oral mucosa. . Table 3 shows the results.

Equation (5) is as follows.
Attached amount change rate (%) = {(Amount of probe attached after swelling of the oral composition of Example 2 (g) - Amount of probe attached after swelling of the comparative composition of Comparative Example 3 (g)) / Comparative Example Amount of attached probe (g) after swelling of the comparative composition of No. 3}×100 (5).

Equation (6) is as follows.
Attached amount change rate (%) = {(Amount of probe attached after swelling of the oral composition of Example 3 (g) - Amount of probe attached after swelling of the comparative composition of Comparative Example 4 (g)) / Comparative Example Amount of attached probe (g) after swelling of the comparative composition of No. 4}×100 (6).

Equation (7) is as follows.
Attached amount change rate (%) = {(Amount of probe attached after swelling of the oral cavity composition of Example 4 (g) - Amount of probe attached after swelling of the comparative composition of Comparative Example 5 (g)) / Comparative Example Probe attachment amount (g) after swelling of the comparative composition of No. 5}×100 (7).

From Table 3, the oral composition of Example 2 showed a change in the amount of adhesion that increased the amount of adhesion by 9.7% relative to the comparative composition of Comparative Example 3. It is understood that the adhesion to is improved. Furthermore, the composition for oral cavity of Example 3 showed a coating amount change rate in which the coating amount increased by 13.5% with respect to the comparative composition of Comparative Example 4, and the composition for oral cavity of Example 4 showed a change rate of 13.5%. 5, the adhesion amount increased by 13.0% with respect to the comparative composition of No. 5. Therefore, for Examples 3 and 4, compared to Comparative Examples 4 and 5, respectively, the amount of adhesion to the oral mucosa It is understood that the adhesion of is further improved.

[Test Example 4]
[Production of oral composition]
The oral compositions of Examples 5 to 8 were produced by preparing each component shown in Table 4 and preparing an oral composition comprising each component according to a conventional method. Furthermore, each component shown in Table 4 was prepared, and a comparative composition of Comparative Example 6 was produced in the same manner as in Examples 5-8. "Carboxyvinyl polymer", "sodium alginate" and "pullulan" in Table 4 are water-soluble polymers and therefore are the second component. "Liquid paraffin" in Table 4 is the third component because it is an oily base. "Allantoin" in Table 4 is a fourth component because it is a non-steroidal anti-inflammatory agent. In each of Examples and Comparative Examples in Test Example 4, the oral ointment in each Example and Comparative Example of Test Examples 1 and 3 was replaced with an oral cream.

[Measurement and evaluation of probe adhesion amount after swelling of oral composition]
To each 2 g of the oral compositions of Examples 5 to 8 and 2 g of the comparative composition of Comparative Example 6, 2 mL of purified water was added, stirred and mixed, and allowed to stand at 30 ° C. for 24 hours to swell. Thus, the swollen bodies of the compositions for oral cavity of Examples 5 to 8 and the swollen bodies of the comparative composition of Comparative Example 6 were obtained. After that, 1.5 g of these swollen bodies were filled in the same 20-mL screw cap bottle as used in Test Example 1, respectively.

Then, using the FUDOH RHEO METER, insert a dedicated probe of φ1 cm toward the surface of the swollen body filled in the screw cap bottle until the tip adheres to the surface of the swollen body, and then at a speed of 2 cm / min. The swollen body was attached to the probe by pulling up the probe, and the amount (mass) of the swollen body attached to the probe was measured.

Based on the above measurements, the probe adhesion amount after swelling of each of the oral compositions of Examples 5 to 8 is calculated by the following formula (8) with respect to the probe adhesion amount after swelling of the comparative composition of Comparative Example 6. ~ (11) by substituting in any of the applicable ones, the oral compositions of Examples 5 to 8 are compared to the comparative composition of Comparative Example 6 as the "adhesion amount change rate (%)", respectively. It was evaluated whether the adhesion to was improved. As in Test Example 1, the "adhesion amount change rate (%)" is a positive number, and when the value is large, the oral composition can be evaluated as having improved adhesion to the oral mucosa. can. Table 4 shows the results.

Equation (8) is as follows.
Attached amount change rate (%) = {(Amount of probe attached after swelling of the oral composition of Example 5 (g) - Amount of probe attached after swelling of the comparative composition of Comparative Example 6 (g)) / Comparative Example Probe attachment amount (g) after swelling of the comparative composition of No. 6}×100 (8).

Equation (9) is as follows.
Attached amount change rate (%) = {(Amount of probe attached after swelling of the oral cavity composition of Example 6 (g) - Amount of probe attached after swelling of the comparative composition of Comparative Example 6 (g)) / Comparative Example Probe attachment amount (g) after swelling of the comparative composition of No. 6}×100 (9).

Equation (10) is as follows.
Attached amount change rate (%) = {(Amount of probe attached after swelling of the oral cavity composition of Example 7 (g) - Amount of probe attached after swelling of the comparative composition of Comparative Example 6 (g)) / Comparative Example Amount of attached probe (g) after swelling of comparative composition No. 6}×100 (10).

Equation (11) is as follows.
Attached amount change rate (%) = {(Amount of probe attached after swelling of the oral composition of Example 8 (g) - Amount of probe attached after swelling of the comparative composition of Comparative Example 6 (g)) / Comparative Example Amount of attached probe (g) after swelling of comparative composition No. 6}×100 (11).

From Table 4, the oral composition of Example 5 showed a change in the amount of adhesion that increased the amount of adhesion by 77.7% relative to the comparative composition of Comparative Example 6. It is understood that the adhesion to is improved. Further, as shown in Table 4, in the oral composition of Example 6 containing allantoin and the oral compositions of Examples 7 and 8 containing two or more types of water-soluble polymers, the adhesion amount change rate was A tendency to increase was confirmed.

[Formulation example]
Some formulation examples using the oral cavity composition according to the present invention are described below. The following formulation examples can be prepared by conventional methods in the formulations described below. The unit of content of each component is w/w%.

[Formulation Example 1] Macrogol Ointment Carbazochrome 0.02
Carboxyvinyl polymer 3
Macrogol 400 48.49
Macrogol 4000 remaining amount 100.0 w/w%.

As a formulation example related to Formulation Example 1, an example in which the macrogol ointment of Formulation Example 1 is filled in a metal container can be given.

[Formulation Example 2] Ointment carbazochrome 0.02
Allantoin 0.3
Carboxyvinyl polymer 2
tocopheryl acetate 2
White petrolatum 30
Microcrystalline wax 2
Bleached Beeswax 2
Peppermint oil 0.1
Gelling hydrocarbon Remaining total amount 100.0 w/w%.

As a formulation example related to Formulation Example 2, an example in which the ointment of Formulation Example 2 is filled in an aluminum container can be given.

[Formulation Example 3] Ointment carbazochrome 0.02
Cetylpyridinium chloride hydrate 0.05
Hinokitiol 0.1
Sodium alginate 3
Gelling hydrocarbon Remaining total amount 100.0 w/w%.

As a formulation example related to Formulation Example 3, an example in which the ointment of Formulation Example 3 is filled in an aluminum container can be given.

[Formulation Example 4] O/W Cream Carbazochrome 0.02
Dipotassium glycyrrhizinate 0.4
Silicic anhydride 1
Liquid paraffin 5
Hydroxypropyl methylcellulose 1
Glycerin 5
Sorbitan monostearate 0.3
Polyoxyethylene hydrogenated castor oil 3
Purified water remaining amount 100.0 w/w%.

As a formulation example related to Formulation Example 4, an example in which the O/W cream of Formulation Example 4 is filled in a laminated container can be given.

[Formulation Example 5] Carbazochrome mouthwash 0.02
ethanol 10
Propylene glycol 10
Sodium lauryl sulfate 0.5
Xylitol 1
Paraben 0.2
carmellose sodium 1
Purified water remaining amount 100.0 w/w%.

As a formulation example related to Formulation Example 5, an example in which the mouthwash of Formulation Example 5 is filled in a container made of polyethylene terephthalate can be given.

Although the embodiments and examples of the present invention have been described as above, it is planned from the beginning that the configurations of the above-described embodiments and examples can be appropriately combined and variously modified. .

The embodiments and examples disclosed this time are illustrative in all respects and should not be considered restrictive. The scope of the present invention is indicated by the scope of the claims rather than the above-described embodiments, and is intended to include meanings equivalent to the scope of the claims and all modifications within the scope.

Claims (7)

a first component that is one or more selected from the group consisting of carbazochrome and salts thereof;
a second component that is a water-soluble polymer;
An oral composition containing
Containing the first component at 0.01 w/w% or more and 0.03 w/w% or less,
Containing 0.1 w/w% or more and 10 w/w% or less of the second component,
The content ratio of the second component to 1 part by mass of the first component is 5 parts by mass or more and 500 parts by mass or less,
The second component is one or more selected from the group consisting of vinyl polymers and polysaccharides.the law of nature,
The vinyl polymer is one or more selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, polyacrylic acid and salts thereof,
The polysaccharides include methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, carboxyethylcellulose, nitrocellulose, chondroitin sulfate, alginic acid, hyaluronic acid, dextran, pullulan, xanthan gum, gellan gum, agar and salts thereof. One or more selected from the group consisting of Oral composition. 2. The oral composition of claim 1, wherein said second component comprises two or more compounds. The oral composition according to claim 1 or 2, which contains a third component that is an oily base. The oral composition according to any one of claims 1 to 3, which contains a fourth component that is a non-steroidal anti-inflammatory agent. 5. The oral composition of claim 4, wherein said fourth component is allantoin. The oral cavity composition according to any one of claims 1 to 5, containing 0.01 w/w% or more and 0.02 w/w% or less of the first component. The oral composition according to any one of claims 1 to 6 , which contains the second component at 1.0 w/w% or more and 5 w/w% or less.